CD63

Across TCGA pan-cancer cohorts, CD63 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD63 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CD63 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD63 expression acts as an unfavorable survival marker.

ACC, CESC, and SKCM are the cancer types where CD63 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.113	0.822	<.001	21	view →
CESC	DFS	Median	III,IV	0.053	0.729	<.001	18	view →
SKCM	DFS	Median	All	0.015	0.758	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD63–ACC (OS)

Open the ACC breakdown →